nach oben

Erschienen in:

01.12.2012 | Leitthema

Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann

verfasst von: L.F. Arenas da Silva, M. Schönthaler, F. Cruz, C. Gratzke, J. Zumbe, A. Stenzl, B. Amend, Prof. Dr. K.-D. Sievert

Erschienen in: Die Urologie | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Als Goldstandard in der medikamentösen Therapie von Patienten mit Beschwerden des unteren Harntraktes („lower urinary tract symptoms“, LUTS) werden α₁-Adrenozeptorblocker und 5α-Reduktaseinhibitoren sowie deren Kombination angesehen. Darüber hinaus kommen Anticholinergika bei Patienten mit überwiegenden Speicherstörungen zum Einsatz, während Phosphodiesterase-5-Hemmer ihr primäres Einsatzgebiet bei Patienten mit LUTS und erektiler Dysfunktion finden. In den letzten Jahren wurde die Suche nach neuen Therapieverfahren intensiviert. Vor allem intraprostatische Injektionstherapien (Botulinumtoxin A, NX-1207, PRX302) und innovative interventionelle Techniken (UroLift®) werden in Hinblick auf ihre Wirkung bei Patienten mit LUTS getestet und scheinen dabei wirksam und sicher zu sein. Besonderes Augenmerk sollte dabei auf den Zusammenhang von LUTS und sexuellen Funktionsstörungen gelegt werden.

Djavan B, Waldert M, Ghawidel C, Marberger M (2004) Benign prostatic hyperplasia progression and its impact on treatment. Curr Opin Urol 14:45–50 PubMedCrossRef

Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36:403–415 PubMedCrossRef

Krambeck AE, Jacobson DJ, McGree ME et al (2012) Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting. BJU Int (Epub ahead of print)

Hyman MJ, Groutz A, Blaivas JG (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166:550–553 PubMedCrossRef

Barkin J, Giddens J, Incze P et al (2012) UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol 19:6217–6222 PubMed

Al-Ansari A, Younes N, Sampige VP et al (2010) GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol 58:349–355 PubMedCrossRef

Melick HH van, Venrooij GE van, Boon TA (2003) Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders. J Urol 170:1851–1855 PubMedCrossRef

McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 338:557–563 PubMedCrossRef

Strittmatter F, Madersbacher S, Stief CG, Gratzke C (2012) Medicinal therapy of benign prostate syndrome. Urologe A 51:1125–1136 PubMedCrossRef

10.

Tatemichi S, Akiyama K, Kobayashi M et al (2006) A selective alpha1 A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J Urol 176:1236–1241 PubMedCrossRef

11.

Prieto L, Romero J, Lopez C et al (2008) Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 81:66–71 PubMedCrossRef

12.

Wilt TJ, Macdonald R, Rutks I (2011) WITHDRAWN: Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev:CD002081

13.

Nejishima H, Yamamoto N, Suzuki M et al (2012) Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia. Prostate 72(14):1580–1587 PubMedCrossRef

14.

Wang C (2010) Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 20:49–54 PubMedCrossRef

15.

Angulo J, Cuevas P, Fernandez A et al (2012) Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 9(9):2293–2306 PubMedCrossRef

16.

Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003 PubMedCrossRef

17.

Oelke M, Giuliano F, Mirone V et al (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61:917–925 PubMedCrossRef

18.

Egerdie RB, Auerbach S, Roehrborn CG et al (2012) Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 9:271–281 PubMedCrossRef

19.

Rick FG, Schally AV, Block NL et al (2011) LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71:736–747 PubMedCrossRef

20.

Siejka A, Schally AV, Block NL, Barabutis N (2010) Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 106:1382–1388 PubMedCrossRef

21.

Debruyne F, Tzvetkov M, Altarac S, Geavlete PA (2010) Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 76:927–933 PubMedCrossRef

22.

Wong WC, Wong EL, Li H et al (2012) Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. J Altern Compl Med 18:54–60 CrossRef

23.

MacDonald R, Tacklind JW, Rutks I, Wilt TJ (2012) Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 109:1756–1761 PubMedCrossRef

24.

Crescioli C, Maggi M, Luconi M et al (2002) Vitamin D3 analogue inhibits keratinocyte growth factor signaling and induces apoptosis in human prostate cancer cells. Prostate 50:15–26 PubMedCrossRef

25.

Crescioli C, Ferruzzi P, Caporali A et al (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol 150:591–603 PubMedCrossRef

26.

Crescioli C, Ferruzzi P, Caporali A et al (2003) Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology 144:3046–3057 PubMedCrossRef

27.

Colli E, Rigatti P, Montorsi F et al (2006) BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49:82–86 PubMedCrossRef

28.

Zahariou A, Karamouti M, Karagiannis G, Papaioannou P (2008) Maximal bladder capacity is a positive predictor of response to desmopressin treatment in patients with MS and nocturia. Int Urol Nephrol 40:65–69 PubMedCrossRef

29.

Goya N, Ishikawa N, Ito F et al (2004) Transurethral ethanol injection therapy for prostatic hyperplasia: 3-year results. J Urol 172:1017–1020 PubMedCrossRef

30.

Grise P, Plante M, Palmer J et al (2004) Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 46:496–502 PubMedCrossRef

31.

Maria G, Brisinda G, Civello IM et al (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62:259–265 PubMedCrossRef

32.

Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA (1998) Botox-induced prostatic involution. Prostate 37:44–50 PubMedCrossRef

33.

Chuang YC, Chiang PH, Huang CC et al (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66:775–779 PubMedCrossRef

34.

Chuang YC, Chiang PH, Yoshimura N et al (2006) Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 98:1033–1337 PubMedCrossRef

35.

Kuo HC (2005) Prostate botulinum A toxin injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 65:670–674 PubMedCrossRef

36.

Guercini F, Pajoncini C, Bard R et al (2005) Echoguided drug infiltration in chronic prostatitis: results of a multi-centre study. Arch Ital Urol Androl 77:87–92 PubMed

37.

Crawford ED, Hirst K, Kusek JW et al (2011) Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol 186:965–970 PubMedCrossRef

38.

Silva J, Silva C, Saraiva L et al (2008) Intraprostatic botulinum toxin type a injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption. Eur Urol 53:153–159 PubMedCrossRef

39.

Silva J, Pinto R, Carvallho T et al (2009) Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: an experimental study in the rat. Eur Urol 56:134–140 PubMedCrossRef

40.

Hamidi Madani A, Enshaei A, Heidarzadeh A et al (2012) Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World J Urol (Epub ahead of print)

41.

Silva J, Pinto R, Carvalho T et al (2011) Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 107:1950–1954 PubMedCrossRef

42.

Chuang YC, Tu CH, Huang CC et al (2006) Intraprostatic injection of botulinum toxin type-A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs. BMC Urol 6:12 PubMedCrossRef

43.

Shore N (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19:305–310 PubMedCrossRef

44.

Singh R, Browning JL, Abi-Habib R et al (2007) Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 18:809–816 PubMedCrossRef

45.

Denmeade SR, Egerdie B, Steinhoff G et al (2011) Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 59:747–754 PubMedCrossRef

46.

Chin PT, Bolton DM, Jack G et al (2012) Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 79:5–11 PubMedCrossRef

47.

Woo HH, Bolton DM, Laborde E et al (2012) Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med 9:568–575 PubMedCrossRef

48.

Woo HH, Chin PT, McNicholas TA et al (2011) Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). BJU Int 108:82–88 PubMedCrossRef

Titel: Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann
verfasst von: L.F. Arenas da Silva
M. Schönthaler
F. Cruz
C. Gratzke
J. Zumbe
A. Stenzl
B. Amend
Prof. Dr. K.-D. Sievert
Publikationsdatum: 01.12.2012
Verlag: Springer-Verlag
Erschienen in: Die Urologie / Ausgabe 12/2012
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-012-3032-1

Neu im Fachgebiet Urologie

24.03.2023 | Diagnostische Radiologie | Podcast | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Neue Behandlungskonzepte von Symptomen des unteren Harntraktes beim Mann

Zusammenfassung

Neu im Fachgebiet Urologie

Künstliche Intelligenz in der Medizin – Hoffnung oder Hype?

Salvage-Bestrahlung wirkt gegen Rezidive von Prostatakrebs

Erhöhtes Melanomrisiko unter PDE-5-Hemmern?

Geringe Krebssterblichkeit nach negativer Prostatabiopsie

Update Urologie

Update Urologie

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Unkonventionelle Behandlungsmethoden in der Urologie

Einlage einer perkutanen Nephrostomie im offenen Magnetresonanztomographen

Die Ergebnisse der ERSPC 2012

Berufspolitik BDU

Mistelpräparate zur Behandlung urologischer Tumoren

Phytotherapie bei benignem Prostatasyndrom und Prostatakarzinom

Neu im Fachgebiet Urologie

Künstliche Intelligenz in der Medizin – Hoffnung oder Hype?

Salvage-Bestrahlung wirkt gegen Rezidive von Prostatakrebs

Erhöhtes Melanomrisiko unter PDE-5-Hemmern?

Geringe Krebssterblichkeit nach negativer Prostatabiopsie

Update Urologie

Update Urologie